17β-エストラディオールは,圧力の過剰負荷による縮症の進行を弱める
M van Eickels1, C Grohé, J P Cleutjens
1Cardiovascular Research Institute Maastricht, University of Maastricht, Netherlands. mvaneickels@lifespan.org
Circulation
|September 19, 2001
まとめ
17β-エストロジオール (E(2) を用いたエストロゲン置換療法は,マウスの心筋縮を効果的に軽減します. このホルモン置換療法には直接的な心臓効果があり,心臓の拡大を緩和することによって,閉経後の女性に潜在的に利益をもたらす可能性があります.
科学分野:
- 心臓病学 心臓病学
- エンドクリノロジー エンドクリノロジー
- 分子生物学は分子生物学である.
背景:
- 心筋縮は,心血管疾患の重要な危険因子です.
- エストロゲン置換療法 (ERT) は心臓保護効果を示しているが,そのメカニズムは不明である.
- 17β-エストラジオール (E(2) は,重要なエストロゲンホルモンである.
研究 の 目的:
- 17β-エストラディオール (E(2) の圧力過負荷による心筋縮に対する効果を調査する.
- E(2) の心臓保護効果の背後にある分子メカニズムを解明する.
主な方法:
- 卵巣切除を受けたマウスは,横動脈収縮 (TAC) または偽手術を受けた.
- マウスはE(2) またはプラセボで治療を受けた.
- 心臓の質量,血液動力学,タンパク質リン酸化 (p38 MAPK,ERK1/2,JNK1/2),遺伝子発現 (ACE,AT1R,ANP) を分析した.
主要な成果:
- E(2) 治療はTAC後の26~31%で心筋縮を著しく減少させました.
- E(2) は,p38-ミトゲン活性化タンパク質キナーゼ (MAPK) の増加したリン酸化を阻害しました.
- (2) 圧力過負荷の心臓における心房内ナトリウレチンペプチド (ANP) 発現の増加.
結論:
- 17β-エストラジオール (E(2)) は,圧力の過剰負荷に対する反応として心筋縮を弱める.
- E(2) を含むERTは,心臓に直接的な有益な効果を発揮する.
- ホルモン置換療法は,閉経後の女性の心筋縮を軽減するための有効な戦略である可能性があります.
関連する概念動画
01:17Antihypertensive Drugs: Action of β1 Blockers
2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:17Hormonal Regulation of Blood Pressure
7.9K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
7.9K
01:29Heart Failure II: Pathophysiology
2.3K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.3K
01:29Hypertension II: Pathophysiology
1.8K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.8K
01:26Cellular Adaptation II: Hypertrophy
78
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy:...
78